5-amino-1MQ with SLU-PP-332 dosage and evidence

What is 5-amino-1MQ with SLU-PP-332?

How does 5-amino-1MQ with SLU-PP-332 work?

5-amino-1MQ blocks NNMT, the enzyme that tags a form of vitamin B3 so the body can clear it. In fat cells in a dish, that raises NAD+ inside the cell and lowers the enzyme's waste product. SLU-PP-332 switches on the three ERR gene switches, most strongly ERR alpha. In mouse muscle, that turns on the same set of genes a bout of aerobic exercise does. Both effects are shown in cells and rodents. Neither has been shown in a person.

What have studies in people found about 5-amino-1MQ with SLU-PP-332?

There is none, for either compound, by any route. That is the most important fact about this product.

• The BPC-157 tablet version: FDA counted five BPC-157 studies in people, with fewer than 110 people in all. None gave it as a shot under the skin, and none lasted more than two weeks. None of them was a tablet. FDA also found mislabelled products on the market.
• 5-amino-1MQ: no study in people. Fat cells in a dish, and mice made fat on a rich diet.
• SLU-PP-332: no study in people. Muscle cells in a dish, and mice.
• No data on how either main compound moves through a person's body. So nothing is known about how much gets in, where it goes, or how fast it clears at these doses.
• The blend: no published study in people or animals.

What this does not tell you: Fat mice respond to lots of things that do nothing in people. And the gap between a mouse turning on exercise genes and a person getting fitter from training is the whole unanswered question in this field.

What do people who took 5-amino-1MQ with SLU-PP-332 report?

This is what real people say happened to them, good and bad. Nobody measured it. A report cannot tell a real effect from the lift people get just from expecting it to work, from a diet or training change made at the same time, or from what was really in the vial. We still put it near the top. It is the next best thing to a study in people: what happens when real people use it, including what goes wrong.

• Better endurance in training after two to three weeks. This is the main claimed effect.
• Less appetite and slow fat loss, which people credit to the NNMT blocker.
• Nothing at all. This is very common.
• Flushing and a warm feeling soon after taking it, reported for the ERR switch-on molecule.
• Nausea and stomach discomfort.
• Arguments about whether any of it gets absorbed, since there is no data on how either compound moves through a person's body.

Sources: Forums including r/peptides and r/nootropics, and vendor product pages. Entirely uncontrolled self-report from people taking unverified material, usually while also training.

The state of the research

The evidence, in charts

The studies we cite

• Review of studies2026
  FDA briefing document on BPC-157 for the July 2026 PCAC meeting

  FDA staff counted every study of BPC-157 in people. They found five, with fewer than 110 people in all. Two were only short conference summaries. None gave it for longer than two weeks. None gave it as a shot under the skin, which is how people use it. Staff found no good human data, and they found products on the market with the wrong label.

  FDA staff counted five published human studies of BPC-157 totalling fewer than 110 subjects, two of them meeting abstracts only, none dosing longer than two weeks, and none giving the peptide by subcutaneous injection. Staff found no adequate human data and mislabelled products in the market.

  Source FDA
• Review of studies2026
  NAD⁺ supplementation for anti-aging and wellness: A PRISMA-guided systematic review of preclinical and clinical evidence

  This review gathers the animal and human evidence on NAD supplements. It matters here because the NNMT blocker's claimed benefit comes from raising NAD in cells. The review is the current summary of how far raising NAD has turned into measured results in people.

  A systematic review of NAD supplementation evidence across preclinical and clinical work. Relevant here because the NNMT inhibitor's claimed benefit runs through raising cellular NAD, and this review is the current summary of how far raising NAD has translated into measured human outcomes.

  PMID 41655607 Ageing Research Reviews
• Animal study2018
  Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice

  In a dish and in mice, this type of molecule blocked the NNMT enzyme cleanly and got into cells easily. In fat cells in a dish, it raised NAD+ inside the cells. In mice made fat on a high fat diet, a strong version reversed the weight gain. This was cells and mice. No person was given it.

  Methylquinolinium NNMT inhibitors showed high membrane permeability and high selectivity, not inhibiting related methyltransferases or NAD salvage pathway enzymes. In cultured adipocytes they reduced intracellular 1-methylnicotinamide and increased intracellular NAD+. A potent inhibitor reversed high fat diet-induced obesity in diet-induced obese mice. Cells and mice, with no human exposure.

  PMID 29155147 Biochemical Pharmacology
• Animal study2023
  Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity

  In muscle cells in a dish, SLU-PP-332 made the cells' energy makers work harder. In mice, it raised the number of endurance-type muscle fibres, let the mice run longer, and switched on the same genes that aerobic exercise does. This was cells and mice. There is no data in people.

  SLU-PP-332 is a synthetic pan agonist at all three estrogen-related receptors with highest potency at ERR alpha. It increased mitochondrial function and cellular respiration in a skeletal muscle cell line, and in mice increased type IIa oxidative skeletal muscle fibres, enhanced exercise endurance and induced an ERR alpha dependent acute aerobic exercise gene programme. Mice, with no human data.

  PMID 36988910 ACS Chemical Biology